ACTUATE THERAPEUTICS, INC.
ACTUATE THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors on July 15, 2029. There is 1 upcoming event on record.
Cash runway is approximately 2.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| July 15, 2029 | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
Track ACTU alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ACTU in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| July 17, 2026 | 8-K filed: Listing / standard notice | Corporate | — |
| June 15, 2026 | 9-ING-41 in Patients With Advanced Cancers | Trial Milestone | Phase 2 |
| May 11, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| May 6, 2026 | 8-K filed: Leadership change, Other event | Corporate | — |
| January 12, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| November 28, 2025 | 8-K filed: Material agreement | Corporate | — |
| November 21, 2025 | 8-K filed: Other event | Filing | — |
| September 10, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| July 7, 2025 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Trial Milestone | Phase 1 |
| June 26, 2025 | 8-K filed: Material agreement | Corporate | — |
| June 5, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| June 2, 2025 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 6, 2025 | 8-K filed: Other event | Filing | — |
| October 13, 2022 | Actuate 1901: 9-ING-41 in Myelofibrosis | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.